Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial.

Go back to Resources

Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Contemporary patterns of spontaneous labor with normal neonatal outcomes.

Go back to Resources

Contemporary patterns of spontaneous labor with normal neonatal outcomes.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

The Advanced Glaucoma Intervention Study: 8. Risk of cataract formation after trabeculectomy.

Go back to Resources

The Advanced Glaucoma Intervention Study: 8. Risk of cataract formation after trabeculectomy.

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma.

Go back to Resources

The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma.

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Meeting highlights: a reappraisal of research results for the local treatment of early stage breast cancer.

Go back to Resources

Meeting highlights: a reappraisal of research results for the local treatment of early stage breast cancer.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Go back to Resources

Clinical trials referral resource. Current phase III, NCI-supported, Cooperative Group Clinical Trials in breast cancer.

Go back to Resources

Clinical trials referral resource. Current phase III, NCI-supported, Cooperative Group Clinical Trials in breast cancer.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

Keywords:

Go back to Resources

Clinical trials referral resource. Current cooperative group phase III clinical trials in early-stage breast cancer.

Go back to Resources

Clinical trials referral resource. Current cooperative group phase III clinical trials in early-stage breast cancer.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

Keywords:

Go back to Resources

Health-Related Quality of Life in children with autism spectrum disorders: results from the autism treatment network.

Go back to Resources

Health-Related Quality of Life in children with autism spectrum disorders: results from the autism treatment network.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Genome-wide association identifies SKIV2L and MYRIP as protective factors for age-related macular degeneration.

Go back to Resources

Genome-wide association identifies SKIV2L and MYRIP as protective factors for age-related macular degeneration.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis.

Go back to Resources

A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 55
  • Page 56
  • Page 57
  • Page 58
  • Current page 59
  • Page 60
  • Page 61
  • Page 62
  • Page 63
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • ISO Certification